Metabolic Signatures for Liver Cancer Diagnosis and Mechanistic Insights: A Large‐Scale, Multicenter Study
Yongjie Xu, Jiachen Wang, Chunmeng Ding, Changfa Xia, Yunyong Liu, Yuanjie Zheng, Sheng Chang, Shaokai Zhang, Yutong He, Ruifang Sun, Yunfeng Xi, Yan Liu, Kun Qian, Wanqing Chen · 2026
Read Metabolic Signatures for Liver Cancer Diagnosis and Mechanistic Insights: A Large‐Scale, Multicenter Study by Yongjie Xu, Jiachen Wang, Chunmeng Ding, Changfa Xia, Yunyong Liu, Yuanjie Zheng, Sheng Chang, Shaokai Zhang, Yutong He, Ruifang Sun, Yunfeng Xi, Yan Liu, Kun Qian, Wanqing Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634481.txt.
Description
Yongjie Xu and co-authors build a blood metabolite test for liver cancer in a 2026 study. Early detection is the weakest link in this cancer's poor outlook. Serum from 1,924 people across eleven centers trains a nine-metabolite signature, read by a nanoparticle boosted mass method. A further 225 people at two centers validate it. Paired with the standard alpha-fetoprotein marker, accuracy runs high in both cohorts.
Early stage cancers are caught with good sensitivity, they report, and the main liver cancer type scores best. One metabolite, nicotinamide, also shows a causal hint for cancer risk. Lab work shows it feeds tumor cell growth and spread through an energy pathway.
Catalog record
| CREATOR | Yongjie Xu, Jiachen Wang, Chunmeng Ding, Changfa Xia, Yunyong Liu, Yuanjie Zheng, Sheng Chang, Shaokai Zhang, Yutong He, Ruifang Sun, Yunfeng Xi, Yan Liu, Kun Qian, Wanqing Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |